Background
==========

*Listeria monocytogenes*(*Lm*) is a Gram-positive, facultative anaerobic bacterium that primarily causes sepsis and meningitis \[[@B1]\] in either immunocompromised or immunocompetent hosts \[[@B2],[@B3]\]. As a foodborne pathogen, it has emerged as a significant public health problem and has caused several epidemics in the United States and Europe. Community-acquired *Lm*meningitis is a serious and life-threatening disease. The estimated incidence is 0.2 cases per 100.000 adults per year in developed countries \[[@B1]\]. *Lm*is the third most frequent cause of community-acquired bacterial meningitis, after *Streptococcus pneumoniae*and *Neisseria meningitidis*aetiologies, due to the vaccine-related decline in *Haemophilus influenzae*type b meningitis \[[@B2]\]. This entity occurs mainly in immunocompromised patients, newborns, and elderly individuals \[[@B4]\], although previously healthy adults can be affected as well \[[@B5]\]. Even with appropriate antibiotic therapy, this entity has a high morbidity and mortality (24%-62%) \[[@B2]-[@B4],[@B6]-[@B8]\].

In this report, we set out to study the incidence and risk factors associated with development of acute community-acquired *Lm*meningitis in adult patients and to evaluate the clinical features, management, and outcome in this prospective case series.

Methods
=======

This is a prospective multicenter observational study carried out in 9 Spanish hospitals. All these hospitals are large institutions with teaching accreditation. The study was conducted over a 39-month period. All patients over 14 years old admitted to the participating hospitals with the diagnosis of acute community-acquired bacterial meningitis (Ac-ABM) were included in this study. The Ethical committees approved the study and did not require informed consent from the patient.

One investigator at each hospital prospectively recorded variables of all Ac-ABM in a previously designed database collecting data on patients\' demography, clinical antecedents, symptoms and signs at admission, laboratory findings, clinical course, treatment, and outcome. Episodes of Ac-ABM were diagnosed on the basis of compatible clinical picture and at least 1 of the following cerebrospinal fluid (CSF) findings: CSF polymorphonuclear (PMN) pleocytosis \[white blood cells (WBC) count \>10/μl, 90% neutrophils, hipoglycorrachia \<40 mg/dL or CSF/blood glucose ratio \<40%, increased protein level \>1 g/L, a positive CSF Gram\'s stain or culture, and/or positive blood cultures. When the CSF Gram\'s stain and blood and CSF cultures were negative, meningitis of unknown aetiology was recorded. Meningitis was considered to be community-acquired whenever a patient had not been previously treated in a hospital. If the patient had been previously admitted, Ac-ABM was diagnosed whenever the onset of the disease occurred 2 weeks after discharge or after 4 weeks if the patient had undergone surgery \[[@B9]\].

*Lm*meningitis was diagnosed in those patients with Ac-ABM in whom *Lm*was isolated in the CSF, blood culture, or both. Serotyping *Lm*was done using specific antisera, as described elsewhere \[[@B10]\].

Patients were considered immunocompromised if they were receiving immunosuppressive therapy and/or had haematological and solid malignancy, connective tissue disease, diabetes mellitus, alcoholism, asplenia, liver cirrhosis, end-stage renal disease, or HIV infection \[[@B11]\]. Patients were considered elderly when they were 60 years or older.

The classic triad was defined when fever, neck stiffness and change in mental status were present. Hyponatremia was defined as a plasma sodium concentration \<135 mmol/L \[[@B12]\]. Focal neurological deficit was diagnosed when aphasia, monoparesis, hemiparesis or cranial nerve palsies were present at admission or during hospitalisation. Cerebellum dysfunction was diagnosed in patients with nystagmus, dysarthria, or limb and gait ataxia.

Time to admission was defined as the appearance of symptoms to admission to the hospital. Patients with impairment of consciousness, neurological deficits, or seizures, underwent cranial computed tomography (CT) before lumbar puncture.

Empiric antibiotic therapy was defined as any parenteral antibiotic capable of crossing the blood-brain barrier, administered for the purpose of treating bacterial meningitis \[[@B8]\]. In the case of *Lm*meningitis, intravenous administration of penicillin, ampicillin, amoxicillin/clavulanic acid, piperacillin/tazobactam, a carbapenem, moxifloxacin or trimethoprim-sulfamethoxazole was considered adequate empirical therapy. During the follow up performance of a brain CT or the administration of adjunctive therapy (corticosteroids and/or phenytoin) were left for the physician in charge to decide.

All patients were followed up until death or hospital discharge. At discharge, all patients underwent a neurological examination, and outcome was measured according to the Glasgow Outcome Scale \[[@B13]\]. A score of 1 on this scale indicates death; a score of 2, a vegetative state; a score of 3, severe disability; a score of 4, moderate disability; and a score of 5, mild or no disability. A favourable outcome was defined as a score of 5, and an unfavourable outcome was defined as a score of 1-4.

For the statistical analysis the SPSS 16.0 software package was used. Univariate analysis of variables from the entire population was performed using unpaired student\'s t-test for parametric continuous variables after correction for equality of variance (Levene\'s test), U Mann-Whitney test for non parametric continuous variables, and Pearson\'s chi-square test or Fisher\'s exact test for categorical variables. Statistical significance was considered when p \<0.05. All p values were two-sided. Furthermore, a multivariate using logistic regression analysis was used to identify independent associations with *Lm*meningitis with results presented as Odds-Ratio (OR) and the 95% confidence intervals (95% CI). Finally, a univariate analysis comparing immunocompromised and immunocompetent patients with *Lm*meningitis was performed as previously indicated.

Results
=======

Two hundred and seventy-eight patients with Ac-ABM were included in this prospective study. The most common pathogen was *Streptococcus pneumoniae*(Table [1](#T1){ref-type="table"}). Forty-six episodes of *Lm*meningitis were identified in 46 patients. Three patients were excluded from the analysis because they were prematurely transferred to another hospital. *Lm*grew from the CSF in 40/43 (93%) cases and from blood culture in 27/43 (63%).

###### 

Aetiologies in 278 episodes of acute community-acquired bacterial meningitis in adults

  Organism                     n(%)
  ---------------------------- ------------
  *Streptococcus pneumoniae*   135 (48.5)
  *Neisseria meningitidis*     63 (22.6)
  *Listeria monocytogenes*     46 (16.5)
  *Haemophilus influenzae*     9 (3.2)
  *Escherichia coli*           4 (1.4)
  *Streptococcus agalactiae*   4 (1.4)
  Others                       17 (6.1)

Table [2](#T2){ref-type="table"} shows the comparison between *Lm*meningitis and episodes with other aetiologies. In this univariate analysis those risk factors and clinical characteristics showing differences at admission were: age, immunosupression, previous otitis, focal neurological deficit, cerebellum dysfunction, WBC count CSF and percentage of neutrophils, CSF/blood glucose ratio, and CSF protein levels. However in the multivariate analysis only age (OR 1.026; 95% CI 1.00-1.05; p = 0.042), immunosupression (OR 2.520; 95% CI 1.05-6.00; p = 0.037), and CSF/blood glucose ratio (OR 39.42; 95% CI 4.01-387.50; p = 0.002) were independently associated with *Lm*meningitis.

###### 

Comparison of episodes of acute community-acquired *Lm*meningitis *versus*other aetiologies

                                                 *Listeria monocytogenes (n = 43)*   Other agents (n = 232)   *p*
  ---------------------------------------------- ----------------------------------- ------------------------ ---------
  Age (median ± IQR)                             69 ± 30                             56 ± 33                  0.019
                                                                                                              
  Gender (male)                                  24 (56) ^d^                         128 (55)                 0.938
                                                                                                              
  Immunocompromised                              29 (67)                             86 (37)                  \<0.001
                                                                                                              
  Previous otitis                                1 (2.1)                             43 (19.5)                0.005
                                                                                                              
  Fever                                          39 (91)                             186 (84)                 0.246
                                                                                                              
  Headache                                       29 (67)                             166 (77)                 0.146
                                                                                                              
  Vomiting                                       20 (46)                             132 (57)                 0.070
                                                                                                              
  Neck stiffness                                 30 (70)                             167 (72)                 0.204
                                                                                                              
  Classic Triad ^a^                              21 (49)                             90 (39)                  0.533
                                                                                                              
  GCS ^b^at admission (median ± IQR)             13 ± 4                              12 ± 4                   0.664
                                                                                                              
  Seizures                                       4 (9)                               17 (7)                   0.688
                                                                                                              
  Focal neurological deficit                     14 (32)                             27 (12)                  0.022
                                                                                                              
  Cerebellum dysfunction                         5 (12)                              5 (2)                    \<0.001
                                                                                                              
  Hyponatremia                                   19 (44)                             60 (26)                  0.066
                                                                                                              
  Duration of symptoms in hours (median ± IQR)   70 ± 53                             48 ± 53                  0.07
                                                                                                              
  WBC count CSF ^c^(median ± IQR)                550 ± 2480                          2860 ± 9380              0.007
                                                                                                              
  CSF neutrophils ( median±IQR)                  70 ± 59                             90 ± 13                  \<0.001
                                                                                                              
  CSF/blood glucose (median ± IQR)               0.26 ± 0.24                         0.09 ± 0.26              \<0.001
                                                                                                              
  Protein level g/L ( median ± IQR)              2.0 ± 1.96                          3.68 ± 5.53              \<0.001
                                                                                                              
  Mortality                                      12 (29)                             36 (16)                  0.059

^a^Triad of fever, neck stiffness and change in mental status.

^b^GCS: Glasgow Coma Scale.

^c^CSF: Cerebrospinal Fluid.

^d^Results are expressed as n (%) unless otherwise specified

All patients with acute community-acquired *Lm*meningitis were immunocompromised or over 50 years old. The baseline characteristics of these patients and the differences between patients with and without immunocompromise are shown in Table [3](#T3){ref-type="table"}. The median age was 69 ± 30 years and 24 of the 43 cases (56%) were male. Twenty-nine (68%) patients were immunocompromised and fourteen (32%) were immunocompetent patients. The nature of immunocompromise were: Twelve (41%) patients were receiving immunosuppressive therapy, 8 (27.5%) had haematological and solid malignancy, 2 (6.8%) with connective tissue disease, 2 (6.8%) with end-stage renal disease and 5 (17.2%) with HIV infection.

###### 

Characteristics of patients with acute community-acquired *Lm*meningitis

  Variable ^a^                                     Patients      Immunocompromised   Immunocompetent   p \*
  ------------------------------------------------ ------------- ------------------- ----------------- -----------
  Number of patients                               43            29                  14                
                                                                                                       
  Age (median ± IQR)                               69 ± 30       69.5 ± 32           64.5 ± 23         1
                                                                                                       
  Elderly (60 years or older)                      24 (56)       16 (55)             8 (58)            0.903
                                                                                                       
  Antibiotic therapy before admission ^b^          3/43 (7)      2/29 (7)            1/14 (7)          0.950
                                                                                                       
  Median time to admission (hours)                 48.5          48                  49                0.500
                                                                                                       
  Time to admission \> 48 h                        22/43 (51)    15/29 (52)          7/14 (50)         0.916
                                                                                                       
  Symptoms at presentation                                                                             
                                                                                                       
    Seizures                                       4/43 (9)      3/29 (10)           1/14 (7)          0.735
                                                                                                       
    Headache                                       29/43 (67)    17/29 (59)          12/14 (85)        0.076
                                                                                                       
    Vomiting                                       20/43 (46)    12/29 (41)          8/14 (57)         0.331
                                                                                                       
    Neck stiffness                                 30/43 (70)    17/29 (62)          12/14 (86)        0.114
                                                                                                       
    Temperature ≥ 38°C                             39/43 (91)    26/29 (90)          13/14 (93)        0.735
                                                                                                       
  Glasgow Coma Scale at admission (median ± IQR)   13 ± 3        13 ± 5              13 ± 1            0.279
                                                                                                       
  Classic Triad ^c^                                21/43 (49)    11/29 (45)          10/14 (71)        **0.039**
                                                                                                       
  Focal neurological deficit                                                                           
                                                                                                       
   Any                                             14/43 (32)    8/29 (28)           6/14 (43)         0.317
                                                                                                       
   Cranial nerve palsies                           7/14 (50)     4/8 (50)            3/6 (50)          1
                                                                                                       
   Large nerve palsies                             2/14 (12)     2/8 (25)            0                 0.186
                                                                                                       
   Cerebellum dysfunction                          5/14 (38)     2/8 (25)            3/6 (50)          0.334
                                                                                                       
  Laboratory findings                                                                                  
                                                                                                       
   Indexes of CSF^d^inflammation                                                                       
                                                                                                       
    WBC count (median ± IQR)                       550 ± 2400    936 ± 3610          310 ± 520         0.069
                                                                                                       
     \< 100 cells/mL                               5/40 (12)     3/27 (11)           2/13 (15)         0.702
                                                                                                       
     100-999 cells/mL                              20/40 (50)    11/27 (40)          9/13 (70)         0.091
                                                                                                       
     \> 999 cells/mL                               15/40 (37)    13/27 (49)          2/13 (15)         **0.045**
                                                                                                       
    Protein level,g/L (median ± IQR)               2.4 ± 2.7     2.39 ± 2.26         2.88 ± 3.16       0.357
                                                                                                       
     Protein level \> 2 g/L                        23/43 (53)    17/29 (67)          6/14 (32)         0.331
                                                                                                       
    % PMN (median ± IQR)                           70 ± 59       70 ± 62             65 ± 48           0.418
                                                                                                       
     \> 50%                                        27/40 (67)    19/27 (67)          8/13 (61)         0.576
                                                                                                       
    CSF/blood glucose (median ± IQR)               0.26 ± 0.23   0.27 ± 0.25         0.22 ± 0.23       0.243
                                                                                                       
   CSF Gram stain                                                                                      
                                                                                                       
    Gram-positive rods                             13/43 (30)    9/29 (31)           4/14 (29)         0.869
                                                                                                       
   Positive CSF culture ^e^                        40/43 (93)    26/29 (67)          14/14             0.212
                                                                                                       
    4b serotype                                    23/28 (82)    12/16 (75)          11/12 (92)        0.355
                                                                                                       
    1/2b serotype                                  5/28 (18)     4/16 (25)           1/12 (8)          0.254
                                                                                                       
   Positive blood cultures                         27/43 (63)    18/29 (62)          9/14 (63)         0.643
                                                                                                       
   Blood analytical findings                                                                           
                                                                                                       
    WBC count (10^9^/L, (median ± IQR)             12 ± 10       10 ± 11             15 ± 5            0.006
                                                                                                       
    Platelets (10^9^/L, median ± IQR)              182 ± 75      161 ± 87            193 ± 70          0.492
                                                                                                       
    Sodium (mEq/L, median ± IQR)                   135.1 ± 4.9   134.2 ± 5           136.9 ± 3.8       0.086
                                                                                                       
    Hyponatremia                                   19/43 (44)    15/29 (51)          4/14 (28)         0.152
                                                                                                       
  Outcome                                                                                              
                                                                                                       
   Unfavorable outcome (GOS^f^\<4)                 15/43 (35)    8/29 (27)           7/14 (50)         0.184
                                                                                                       
   Mortality                                       12/43 (28)    7/29 (24)           5/14 (35)         0.482

**^a^**Results are expressed as n (%) unless otherwise specified

**^b^**Use of at least two doses of an oral or parenteral antibiotic within one week of the onset of meningitis.

^c^Triad of fever, neck stiffness and change in mental status.

^d^CSF: Cerebrospinal Fluid.

^e^The serotype identification only was done in 28 patients.

^f^GOS: Glasgow Outcome Scale.

In our series, in patients with *Lm*meningitis, fever was the most common symptom (91%). The majority of patients also had altered mental status at presentation, while headache was present in nearly half the patients. The classic triad of fever, neck stiffness and altered mental status was present in 21 (49%) patients; however, almost all patients (95%) had at least 1 or more of these symptoms. Thirty-two percent of the patients had focal neurological findings at presentation, 12% presented cerebellum dysfunction, and 9% had seizures. The most frequent focal neurological finding was cranial nerve palsies. The median duration of symptoms before admission to the hospital was two days. Immunocompromised patients had a lower incidence of the classic triad (45% *vs*. 71%; p = 0.039), headache (59% vs 85%; p = 0.076), and focal neurological deficit at presentation (28% vs 43%; p = 0.317) as compared with immunocompetent patients with acute community-acquired *Lm*meningitis.

Thirty-nine (91%) patients underwent CT in the emergency department. In 30 of 39 (77%), there were no abnormalities associated with the listerial infection. In the remaining 9 (23%) patients, the most common findings were focal lesions and/or hydrocephalus. All patients with hydrocephalus were treated neurosurgically.

Lumbar puncture was performed in all patients. CSF findings are outlined in Table [3](#T3){ref-type="table"}. There was no relation between low CSF leukocyte count and age or immunocompromise. The most frequently found serotype was the 4b in 23 (82%) of 28 cases.

Empirical antimicrobial therapy was intravenous ampicillin (2 g every four hours) for 34 (79%) of 43 patients, in 11 (32%) of them combined with aminoglycosides. The rest of six patients received trimethoprim-sulfamethoxazole therapy in two cases and meropenem in the other four cases as empirical antibiotic treatment. Three patients that did not received appropiated empirical treatment receiving ceftriaxone plus vancomycin. Twenty-one patients (49%) received adjunctive therapy with dexamethasone; in 14 cases, the first dose was given previously or concomitantly to the first antibiotic dose, and eleven patients received phenytoin. There were no major side-effects of dexamethasone therapy (gastro-intestinal bleeding, hyperglycemia).

The overall mortality was 28% (12 of 43 patients) and five of thirty-one (16.1%) surviving patients had a neurological deficit at discharge. Neurological abnormalities identified were cranial nerve palsies in 2 (6.4%) and hemiparesis in 3 (9.6%). No patients had hearing impairment. Definitive ampicillin plus gentamicin therapy was significantly associated with unfavourable outcome (67% vs 28%; p = 0.024) and a higher mortality (67% vs 32%; p = 0.040) due to *Lm*infection, Table [4](#T4){ref-type="table"}.

###### 

Description of patients with acute community-acquired *Lm*meningitis who survivied or died

                                               Survivors n = 31   Non-Survivors n = 12   *p*
  -------------------------------------------- ------------------ ---------------------- -----------
  Age (median ± IQR)                           67 ± 26            71 ± 43                0.999
                                                                                         
  Elderly patient                              17 (55)            7 (58)                 0.836
                                                                                         
  Immunocompromised                            22 (71)            7 (58)                 0.482
                                                                                         
  Neurological finding                         9 (29)             2 (17)                 0.698
                                                                                         
  GCS^b^at presentation (median ± IQR)         13 ± 11            13 ± 8                 0.453
                                                                                         
  Classic Triad^c^                             14 (45)            7 (58)                 0.438
                                                                                         
  WBC \> 999 cells/mL                          10 (33)            5 (42)                 0.282
                                                                                         
  Protein level g/L (median ± IQR)             2.08 ±1.3          2.1 ± 4.4              0.685
                                                                                         
  CSF^d^/blood glucose ratio (median ± IQR)    0.27 ± 0.24        0.18 ± 0.21            0.448
                                                                                         
  Hyponatremia                                 13 (42)            6 (50)                 0.633
                                                                                         
  Seizures                                     2 (7)              2 (17)                 0.308
                                                                                         
  Empirical Ampicilllin + gentamicin therapy   8 (26)             3 (25)                 0.957
                                                                                         
  Definitive Ampicillin + gentamicin therapy   10 (32)            8 (67)                 **0.040**
                                                                                         
  Dexamethasone concomitant to antibiotic      17 (55)            4 (33)                 0.206
                                                                                         
  Phenytoin                                    8 (26)             3 (25)                 0.999

**^a^**Results are expressed as n (%) unless otherwise specified

^b^GCS: Glasgow Coma Scale.

^c^Triad of fever, neck stiffness and change in mental status.

^d^CSF: Cerebrospinal Fluid.

Discussion
==========

Early administration of adequate antimicrobial therapy is the cornerstone of treatment in patients with meningitis. Despite developments in antimicrobial agents, *Lm*meningitis is still a serious disease that carries high morbidity and mortality rates. A relevant aspect in this study is the prospective inclusion of adult patients with acute community-acquired *Lm*meningitis, to evaluate risk factors associated with *Lm*aetiology which should contribute to early appropriate antimicrobial therapy of this serious and life-threatening disease. Thus, in a large cohort of patients with Ac-ABM, our study reveals that elderly, immunocompromised patients, and a higher CSF/blood glucose ratio were independently associated with isolation of *Lm*as the responsible pathogen.

In our own series, the incidence of acute community-acquired *Lm*meningitis in adults was 16.5% (46/278). Previously, in a multicenter study \[[@B14]\] conducted in the United States, the authors reported that *Lm*accounted for 8% of the cases of bacterial meningitis. Other studies from Europe and North America have reported incidences of 5%-10% or more among all episodes of Ac-ABM among adults \[[@B15]-[@B18]\]. Over a 36-year period, Durand *et al.*described that *Lm*accounted for 11% of the episodes of Ac-ABM in adults \[[@B7]\]. The probable increase in the incidence may be attributed to longer life expectancy, changes in diet or food processing, and the higher number and longer survival of immunocompromised people \[[@B2]\].

On the other hand, symptoms and signs of patients presenting with *Lm*meningitis were not different from those found in the general population of patients with Ac-ABM, according to previous studies \[[@B19]\].

The CSF profile in patients with *Listeria*infection revealed significantly fewer WBC and lower protein concentrations than patients with infection due to other pathogens, and a trend towards less hypoglycorrhachia and a lower percentage of PMNs. However, these findings do not apply to all cases \[[@B20]\]. In the appropriate clinical situation, clinicians should not exclude *Lm*based on the degree of pleocytosis, the percentage of PMNs, or the concentration of glucose or protein in the CSF.

The experience in the present series suggests that the Gram stain is negative in two-thirds of the cases of *Lm*meningitis, and may be misleading in many of the remaining cases. Clinicians should be aware of these difficulties, inform the microbiology department when they suspect this pathogen, and not rule out *Lm*based on Gram stain alone. Furthermore, despite the diversity of serotypes of *Lm*, only three serotypes are responsible for \>90% of human disease: 1/2a, 1/2b, and 4b. The majority of strains were serotype 4b \[[@B21]\] (23 of 28 cases; 82%), suggesting that serotype 4b of *Lm*is more virulent than others. Otherwise, blood cultures were positive in more than half of the cases in the present series. Some reports advocate the use of the polymerase chain reaction or immunoassays for the early detection of *Lm*\[[@B22],[@B23]\], but these techniques need further evaluation.

Most patients in our case series received appropriated empirical therapy, 40/43 (93%), in 11 of them associated to aminoglycosides. Our study showed that a definitive combined therapy with aminoglycosides was significantly associated with an increasing trend for an unfavourable outcome and mortality, which corresponds with a previous study \[[@B24]\]. These results could be explained by *Lm*meningitis patients have an associated co-morbid condition, in which addition of an aminoglycoside may be harmful. For this reason, actually this combined therapy is been questioned, moreover of the drug\'s associated nephrotoxicity and inability to cross the blood-brain barrier. In this way, every case should be approached independently, although certain subsets of patients probably require empiric antibiotic treatment for *Lm*, such as patients over 45-50 years of age, patients with immunosuppression, a higher CSF/blood glucose ratio, or patients with a Gram stain of CSF revealing Gram-positive bacilli \[[@B19]\], and the associated with aminoglycosides should be avoid in order to improve patient\'s outcome.

A significant number of patients, 5 of 31 (16.1%) of the survivors in the present series had some degree of residual neurological deficit at hospital discharge. Although an even higher incidence of residual neurological deficits (32%) was noted among survivors enrolled in 3 previous series and deficits persisted for more than a year in 4 of 10 of those cases with adequate follow up \[[@B25]-[@B27]\].

Moreover, mortality due to *Lm*is among the highest of all causes of acute bacterial meningitis \[[@B28]\]. Part of the high mortality of *Listeria*infection may relate to the increased number of immunocompromised and older patients affected by this pathogen \[[@B29],[@B30]\]. Although evidence for use of anticonvulsant prophylaxis in *Lm*meningitis is lacking, it may be considered as seizures have previously been related to increases mortality \[[@B31]\], as did we in the present series, although this was not statistically significant. Further studies are needed in order to clarify this point.

Finally, the role of adjunctive therapy with corticosteroids has been widely debated. A clinical trial showed a beneficial effect of early dexamethasone treatment in adults with bacterial meningitis \[[@B32]\]. Nevertheless, there are no studies on the effect of dexamethasone in adult *Listeria*meningitis. We observed a higher survival rate among those patients that received dexamethasone concomitant to antibiotic, although this association did not reach statistical significance. Our results suggest that further studies are needed to evaluate the effect of corticosteroid therapy in adult patients with *Lm*meningitis.

The present study has several limitations. First, given the small number of patients, we were unable to develop a statistical model to identify risk factors independently associated with a poor outcome or death in patients with acute community-acquired *Lm*meningitis. Secondly, only patients who underwent lumbar puncture and who had a positive cerebrospinal fluid culture were included. Negative cerebrospinal fluid cultures occur in 20 percent of patients with acute community acquired bacterial meningitis. Third, delay of antimicrobial therapy was not recorded. Despite all these limitations, we consider that this study contributes to our knowledge of risk factors associated with development of acute community-acquired *Lm*meningitis, and to evaluating epidemiology, clinical features, management, and outcome in this homogenous population of adult patients with acute community-acquired *Lm*meningitis.

Conclusions
===========

To sum up, our study showed elderly or immunocompromised patients and a higher CSF/blood glucose ratio in patients with Ac-ABM must alert clinicians about *Lm*aetiology. Furthermore, we observed a high incidence of acute community-acquired *Lm*meningitis in adults and the addition of aminoglycosides to treatment should be avoid in order to improve the patients\' outcome. Nevertheless, despite developments in intensive care and antimicrobial therapy, this entity is still a serious disease that carries high morbidity and mortality rates. Further studies should focus on specific interventions (e.g. adjuvant therapies) that could help to improve the poor prognosis of these patients.
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